Moneycontrol
Get App
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Venus Remedies

Venus Remedies

BSE: 526953|NSE: VENUSREM|ISIN: INE411B01019|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
, 16:01
24.00
0
VOLUME 4,334
LIVE
NSE
Jan 24, 15:43
23.60
-0.4 (-1.67%)
VOLUME 5,280
News on Venus Remedies
Select Year: 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Venus gets market authorization for Meropenem from Switzerland

1.27 pm | 11 Nov 2014 |  Source: Moneycontrol.com

Venus Remedies has achieved yet another landmark by receiving marketing authorization in Switzerland through its German subsidiary Venus Pharma GmbH f...

See CRISIL upgrade & new registrations soon: Venus Remedies 

3.46 pm | 25 Sep 2014 |  Source: CNBC-TV18

After a 7-year long wait to launch the product, the Panchkula-based company has been granted market authorisation and patent for this product from Sin...

Venus forays into Singapore's topical pain management market

11.46 am | 25 Sep 2014 |  Source: Moneycontrol.com

This is to inform you that Venus Remedies Limited has entered Singapore's topical pain management market with a marketing authorisation and patent for...

Your Stocks: Top chart picks by market experts 

3.46 pm | 16 Sep 2014 |  Source: CNBC-TV18

Watch the interview of Vishal Malkan, CMT at malkansview.com and Lancelot D'Cunha, CEO of ITI Wealth Management Pvt Ltd with Reema Tendulkar & Sumaira...

Exit Venus Remedies, says Lancelot D'Cunha 

3.30 pm | 16 Sep 2014 |  Source: CNBC-TV18

Lancelot D'Cunha, CEO at ITI Wealth management is of the view that one may exit Venus Remedies....

Buy Pidilite, Tata Sponge, Venus Remedies: Manav Chopra 

12.59 pm | 10 Sep 2014 |  Source: CNBC-TV18

Manav Chopra of Nirmal Bang recommends buying Biocon for a target price of Rs 520 and Venus Remedies for a target price of Rs 370....

Bull's Eye: Buy Venus Remedies, TNPL; short HDIL, Unitech 

8.48 am | 10 Sep 2014 |  Source: CNBC-TV18

Dharmesh Kant, IndiaNivesh Securities Private Limited advises buying Tamil Nadu Newsprint and Papers for a target price of Rs 172 and Pratibha Industr...

Venus ties up with Mylan for marketing meropenem in three European countries

10.45 am | 08 Sep 2014 |  Source: Moneycontrol.com

Venus Remedies wholly owned subsidiary has entered into a distribution-cum-outlicensing agreement with Mylan for marketing its generic broad-spectrum...

Venus Remedies enters into agreement with TEVA

12.22 pm | 04 Sep 2014 |  Source: Moneycontrol.com

Venus Remedies has recently entered into a collaborative agreement with TEVA for a block buster Anti Cancer drug....

Venus Remedies gets first marketing authorisation in Switzerland for Gemcitabine

1.16 pm | 20 Aug 2014 |  Source: Moneycontrol.com

Venus Remedies has achieved yet another landmark by receiving its first marketing authorization in SWITZERLAND from Swiss drug authority (SWISSMEDIC) ...

Buy Venus Remedies; target of Rs 360: Sunidhi Securities

12.54 pm | 24 Jul 2014 |  Source: Moneycontrol.com

Sunidhi Securities is bullish on Venus Remedies and has recommended buy rating on the stock with a target of Rs 360 in its July 23, 2014 research repo...

Bull's Eye: Buy Wockhardt, South Indian Bank, BGR Energy 

9.02 am | 07 Jul 2014 |  Source: CNBC-TV18

Manav Chopra, Nirmal Bang advises buying Wockhardt for a target price of Rs 650 and Allahabad Bank for a target price of Rs 150....

Hope to launch Elorus in Europe in FY15: Venus Remedies 

4.35 pm | 04 Jun 2014 |  Source: CNBC-TV18

The drug player already has European approval for its key drugs like Elorus, Potentox, Vancoplus and market authorisation of these drugs have also bee...

Venus gets European patent for antibiotic drug

6.53 pm | 03 Jun 2014 |  Source: PTI

The product is designed for mixed multi-drug infections for pediatric, geriatric and adult immuno-compromised patients where the risk of adverse event...

Venus to sell Meropenem in Australia; ties up with Lupin

4.17 pm | 19 May 2014 |  Source: PTI

The Panchkula-based company said it plans to roll out the drug by the third quarter of 2014 and is eyeing sizeable share in Australia's USD 15 million...

Bull's Eye: Buy MCX India, TVS Motor, ICICI Bank, REC 

9.05 am | 12 May 2014 |  Source: CNBC-TV18

Kunal Saraogi of Equityrush recommends buying YES Bank with a target of Rs 510 and ICICI Bank with a target of Rs 1425....

Buy pharma stocks on dip, says Prakash Diwan 

1.24 pm | 10 Apr 2014 |  Source: CNBC-TV18

Prakash Diwan, director at Altamount Capital Management advises buying pharma stocks on declines....

Meropenem will give us 25-30% growth Y-oY: Venus Remedies 

3.28 pm | 04 Apr 2014 |  Source: CNBC-TV18

Exports constitute around 32 percent of Venus Remedies' topline, out of which two-third comes from developed countries and one-third from the rest of ...

Venus Remedies gets marketing nod from Venezuela for meropenem

3.16 pm | 03 Apr 2014 |  Source: Moneycontrol.com

Venus Remedies has extended its footprint in Latin America with marketing authorization for meropenem from Venezuela, a USD 6 billion pharmaceutical m...

Venus Remedies standalone Dec '13 sales at Rs 131.26 crore

5.42 pm | 13 Feb 2014 |  Source: Moneycontrol.com

Venus Remedies has reported a sales standalone turnover of Rs 131.26 crore and a net profit of Rs 17.23 crore for the quarter ended Dec '13...

1 2
Quick Links for Venus Remedies
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.